Hemispherx Notes the Importance of Immunizations During Upcoming National Immunization Awareness Month and Potential of Ampligen in Influenza Vaccine Strategies

by Barry101 | Jul 3, 2018 | Press Release

ORLANDO, Fla., July 03, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), an immuno-pharma R&D company focused on unmet medical needs in immunology, is pleased to enthusiastically support National Immunization Awareness Month (NIAM), which is observed...

Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina

by Barry101 | Jun 27, 2018 | Press Release

ORLANDO, Fla., June 27, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) has announced the immediate expansion of its Treatment Protocol/Expanded Access Programs for ME/CFS in the United States, known as AMP-511, to new enrollees for the first time in more...

Hemispherx Releases First 8,500 Vial Lot of Ampligen to Supply Expanded Access Programs in the United States, Europe and Canada for ME/CFS and Pancreatic Cancer and Announces Successful Finish of Second Commercial Size Lot

by Barry101 | Jun 15, 2018 | Press Release

Balance for New Cancer Clinical Trials; Second Commercial-Size Batch Now in Regulatory TestingORLANDO, Fla., June 15, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) has announced the successful completion of the first phase of its Ampligen production...

Hemispherx Announces New Data Showing Ampligen’s Positive Role in Reprograming Tumor Microenvironment

by Barry101 | Jun 5, 2018 | Press Release

Study Results Suggests Ampligen Could Materially Enhance the Effectiveness of Checkpoint Blockade TechnologyORLANDO, Fla., June 05, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that its TLR3 agonist Ampligen outperformed two other TLR3...

Hemispherx Biopharma and Roswell Park Plan Phase I/II Study of Ampligen Plus Checkpoint Inhibitors

by Barry101 | May 31, 2018 | Press Release

Earlier Studies Showed Ampligen Produced a More Favorable Ratio of Killer T cells to Regulatory T cells in the Tumor Microenvironment, a Key to Improving Checkpoint Blockade TherapyORLANDO, Fla., May 31, 2018 — Roswell Park Comprehensive Cancer Center (Roswell...

CORRECTING AND REPLACING: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update

by Barry101 | May 16, 2018 | Press Release

ORLANDO, Fla., May 16, 2018 — In a release issued earlier today by Hemispherx Biopharma, Inc. (NYSE American:HEB) with the same headline, the net loss from operations was incorrect in the fourth paragraph. It should say $0.07 per share, not $0.70 per share....